Highly rated in
Highly rated in
Check Dr. James D. Battiste's experience treating your condition:
About Dr. James D. Battiste

James Battiste is a Neurologist in Oklahoma City, Oklahoma. Battiste has been practicing medicine for over 16 years and is highly rated in 22 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Awake Craniotomy. He is licensed to treat patients in Texas. Battiste is currently accepting new patients.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 21 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. James D. Battiste it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. James D. Battiste accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health

Call to see if your plan is accepted.
800 Ne 10th St, Oklahoma City, OK 73104
Other Locations
1000 N Lincoln Blvd, Oklahoma City, OK 73104
Background & Education
Graduate Institution
University Of Texas Southwestern Medical School At Dallas, 2007
Psychiatry & Neurology in TX
Hospital Affiliations
Jackson County Memorial Hospital
OU Health - University Of Oklahoma Medical Center
INTEGRIS Baptist Medical Center
Duncan Regional Hospital
Norman Regional Hospital
Oklahoma Childrens Hospital At OU Health
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of Niraparib in Patients With Recurrent Glioma
Feasibility Pilot Study of OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Genomically-Guided Treatment Trial in Brain Metastases
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
View 13 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors